Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06750094
Title	A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3)
Acronym	OrigAMI-3
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Janssen Research & Development, LLC
Indications	colon adenocarcinoma rectum adenocarcinoma
Therapies	Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin
Age Groups:	senior \| adult
Covered Countries	USA \| AUS